Part of any investors DD is to attempt to understand the platforms that a drug delivery company makes. PSDV is fairly diverse here. When I propose to you that a company like REGN "MAY" have a tech agreement with PSDV, you respond by saying ALIM has all the rights wrapped up with the steroid Fa. to be delivered with Durasert. However, Tethadur is "THE" platform I was referring to. PSDV's greatest technology potentially is this very unique bioerodible biosilicon protein delivery platform. Drugs like Lucentis and Avastin (Roche) and Eylea (REGN) are drugs that get inserted for various ailments of the eye, but have to be repeated monthly or every 6 weeks in the case of Eylea. Now.....PSDV has the potential to take these type of drugs and put them into their "Tethadur" platform, which then can potentially can provide sustained release over a period of 6 months. This is the most promising platform in PSDV's pipeline, these drugs that I've mentioned here "MAY"need this very platform to minimize these frequent injections. In ending, this will have nothing to do with ALIM.
Yes of course I suppose that's a possibility. I didn't realize that you were talking about unknown development that might generate revenues in the next decade. I prefer to focus my attention on the nearer term.
cva, I'm sorry. Medidur carries Fa, Durasert will carry Latanoprost for PFE (glaucoma)
Perhaps you recall the new designation just announced by the FDA; "Breakthrough"designation. I'm not sure, but "IF"there were a therapy that dealt with blindness (which is kind of "FINAL") breakthrough designation may start to apply for blindness prevention.